The U.S. Food and Drug Administration (FDA) has approved the first once-daily oral PCSK9 inhibitor for adults with high levels of low-density lipoprotein (LDL) cholesterol, commonly known as “bad” cholesterol.
The newly approved medication provides an alternative to injectable PCSK9 inhibitors that have been used in recent years to help lower LDL cholesterol in eligible patients. Health experts say the approval expands the range of treatment options available for people who require additional cholesterol-lowering therapy.
What Is LDL Cholesterol?
LDL cholesterol is often referred to as “bad” cholesterol because high levels can contribute to the buildup of fatty deposits in the arteries. Over time, this buildup may increase the risk of heart attack, stroke, and other cardiovascular diseases.
Doctors typically recommend lifestyle changes such as a balanced diet, regular exercise, and smoking cessation as the first steps in managing cholesterol. When these measures are not enough, medications may be prescribed based on an individual’s medical history and overall cardiovascular risk.
How the New Medication May Help
According to the FDA, the newly approved oral PCSK9 inhibitor is intended for certain adults who need additional LDL cholesterol reduction despite existing treatment.
Unlike earlier PCSK9 therapies that are administered by injection, the new medicine is taken as a tablet once a day, which may offer greater convenience for some patients.
Healthcare professionals note that treatment decisions should always be based on an individual’s medical needs and should be made in consultation with a qualified healthcare provider.
Experts Welcome Additional Treatment Option
Cardiovascular specialists say the approval represents an important development in cholesterol management because it offers another option for patients who may not achieve their target cholesterol levels with existing therapies.
However, experts also emphasize that medication is only one part of heart health. Maintaining a healthy lifestyle, following prescribed treatments, and attending regular medical check-ups remain essential for reducing cardiovascular risk.
Patients Should Consult Healthcare Providers
Medical experts advise patients not to start, stop, or change any cholesterol medication without first consulting their healthcare provider.
People concerned about their cholesterol levels should speak with a doctor, who can recommend appropriate testing and discuss the most suitable treatment options based on their health condition.
